Abstract. A thermostable suppository of artesunate (artesunic acid) has been developed. In Gabon, 12 children with Plasmodium falciparum malaria received two administrations of this suppository in a 4-hr interval. Parasitemia and fever were then measured and the plasma levels of artesunate and its active metabolite, dihydroartemisinin, were determined by means of a reversed phase high-pressure liquid chromatography method using reductive electrochemical detection. Substantial parasite clearance (97-100%) was noted 24 hr after the beginning of the treatment and body temperature had returned to normal. Absorption, metabolism, and elimination of artesunate were rapid. Mean values of maximum plasma levels (Cmax) and maximum concentration peak times (tmax) were evaluated. The Cmax of dihydroartemisinin (0.18 Ϯ 0.10 g/ml [mean Ϯ SE]) was higher than the Cmax of artesunate (0.09 Ϯ 0.04 g/ml) and the tmax of dihydroartemisinin (1.13 Ϯ 0.58 hr) was higher than the tmax of artesunate (0.58 Ϯ 0.19 hr). Plasma levels 30 min after the second suppository administration were not consistently higher than those found 30 min after the first administration.
Each year malaria causes more than one million deaths of children in Africa. 1 The search for new antimalaria drugs, including new pharmaceutical forms adapted to children, is urgent. Artemisinin compounds have been shown to be extremely potent against malaria, 2 even in areas where multidrug resistance of Plasmodium falciparum occurs. Although it has been estimated that more than two million cases of malaria have been treated with artemisinin or its derivatives, 2 the available pharmacokinetic data are still insufficient to assess the accuracy of most recent pediatric therapeutic regimens. 2, 3 Artesunate (artesunic acid), a semisynthetic derivative of artemisinin, is of particular interest since its solubility in water facilitates its absorption. 4 A new pharmaceutical form of the drug has been developed: thermostable suppositories containing 50 mg of artesunate. This formulation can easily be administered in the field and is especially convenient for small children or patients unable to swallow. The absorption rate of its active component is often as rapid as that obtained using intra-muscular administration. 5 Thermostable, it does not need to be kept in a refrigerator.
The aims of this study were to quantify plasma levels and study kinetics of artesunate and its active metabolite, dihydroartemisinin, in African children with uncomplicated P. falciparum malaria after administration of 50-mg rectal artesunate.
To verify whether higher plasma levels would be reached after a second dose than after a single administration, a second suppository containing 50 mg of artesunate was administered 4 hr after the first administration. This time interval was chosen in accordance with a Chinese therapeutic protocol. 6, 7 Parasitemia and fever were measured to follow the evolution of the disease and evaluate the suitability of the present regimen.
SUBJECTS, MATERIALS, AND METHODS
The clinical part of the present study was performed at the Albert Schweitzer Hospital in Lambarene, Gabon. The study was approved by the Ethics Committee of the International Foundation of the Albert Schweitzer Hospital. Twelve children (Table 1 ) from Gabon were included in this study. Informed consent was obtained from parents or legal guardians of these children. They all fulfilled the following inclusion criteria: uncomplicated P. falciparum malaria with a parasitemia level between 500 and 100,000 parasites/l, and an age between 7 and 12 years. None of the children had any of the following exclusion criteria: severe malaria, diarrhea, other severe disorders, intake of coffee, tea, Coca Cola (Atlanta, GA), or other methylxanthine derivatives in the last 4 hr prior to admission, and a positive urine test result for chloroquine and sulfonamides.
Plasmotrim Rectocaps (50 mg, batch no. 95180), the thermostable suppositories of artesunate used in this study were manufactured by MEPHA Ltd., (Aesch-Basel, Switzerland). Each of them contains 50 mg of artesunate encapsulated as an oily solution into a torpedo-shaped, gelatin capsule shell (volume ϭ 0.592 cm 3 ). All subjects received two administrations of one suppository with a 4-hr interval. For ethical reasons due to the possible recurrence of the disease and the young age of the children, the treatment was continued with a single dose of sulfadoxine and pyrimethamine 20 hr after the second artesunate administration.
Thick blood film parasite counts and fever measurements were performed before and at 6, 12, and 24hr after the first administration. Blood samples (3 ml) were collected at 30min, 1 hr, and 3 hr after the first administration, as well as 30 min after the second administration into tubes treated with EDTA. These samples were then centrifuged, and the plasma was immediately taken and kept frozen at -80ЊC until drug quantification.
Artesunate and its active metabolite dihydroartemisinin were extracted from the plasma before quantification (solidphase extraction, cartridges C-18 Sep-Pak; Supelco, Bellefonte, PA) according to the technique described by Benakis and others. 8, 9 The quantification of artesunate and dihydroartemisinin was performed using a reversed-phase, high-pressure liquid chromatography (HPLC) method with electro- 8, 9 Artesunate and dihydroartemisinin plasma levels were measured above the detection limit of 0.02 g/ml.
To validate the analytical procedure, two sets of six replicate extraction and quantification experiments were performed on blank plasma samples spiked with known amounts of artesunate and dihydroartemisinin. The recovery values (Ϯ SE ) for the plasma samples spiked with 0.3 g/ml and 1.0 g/ml of artesunate were 90.2 Ϯ 2.8% and 98.0 Ϯ 2.5%, respectively. For the plasma spiked with 0.2 g/ml and 1.0 g/ml of dihydroartemisinin, they were 91.5 Ϯ 1.4% and 95.2 Ϯ 3.1% respectively.
RESULTS
A significant parasite clearance (97-100%) was noted and body temperature had returned to normal 24 hr after the beginning of the treatment ( Table 2 ). The plasma levels of artesunate and its active metabolite, dihydroartemisinin, were determined for each subject. In spite of the relatively small number of blood samples collected for each patient, an interpretation of these plasma levels versus time with extrapolation is presented in Figure 1 . Maximum plasma levels (Cmax) and maximum concentration peak times (tmax) were then compared. Mean Ϯ SE values corresponding to artesunate and dihydroartemisinin Cmax and tmax values before the second suppository administration were artesunate Cmax ϭ 0.09 Ϯ 0.04 g/ml, artesunate tmax ϭ 0.58 Ϯ 0.19 hr, dihydroartemisinin Cmax ϭ 0.18 Ϯ 0.10 g/ml, dihydroartemisinin tmax ϭ 1.13 Ϯ 0.58 hr.
In the cases of subjects K and L, no absorption was found after the second administration of artesunate. It cannot be excluded that the second suppository was expelled during defecation in these cases. The mean artesunate concentrations and the mean dihydroartemisinin concentrations 30 min after the first suppository administration and 30 min after the second suppository administration were then calculated excluding data for subjects K and L. Thirty minutes after the first artesunate administration, the mean Ϯ SE artesunate concentration was C t1 ϭ 0.5 hr ϭ 0.08 Ϯ 0.04 g/ml and the mean Ϯ SE dihydroartemisinin concentration was C t1 ϭ 0.5 hr ϭ 0.12 Ϯ 0.07 g/ml. Thirty minutes after the second artesunate administration, the mean Ϯ SE artesunate concentration was C t2 ϭ 0.5 hr ϭ 0.08 Ϯ 0.04 g/ml and the mean Ϯ SE dihydroartemisinin concentration was mean C t2 ϭ 0.5 hr ϭ 0.13 Ϯ 0.08 g/ml. Artesunate was well tolerated and no adverse effects occurred in this study.
DISCUSSION
For all subjects, the kinetic profiles of artesunate and dihydroartemisinin were similar with rapid absorption, metabolism, and elimination. In 10 of the 12 subjects, the dihydroartemisinin Cmax was greater than the artesunate Cmax and the dihydroartemisinin tmax was greater than the artesunate tmax. The kinetic profiles for all subjects confirmed that dihydroartemisinin is a major metabolite of artesunate. When artesunate and dihydroartemisinin plasma levels of all subjects were compared, significant interindividual variation in the intensity of artesunate resorption was noted. This variation might be due to the rectal route used because it involves individual physio-anatomic factors in the absorption of a compound after a suppository administration. 5 A comparable interindividual variation in artesunate resorption was also noted in a previous pharmacokinetic study in healthy adult volunteers after administration of suppositories containing 200 mg of artesunate. 8 A comparison of the mean artesunate C t1 ϭ 0.5 hr with the mean artesunate C t2 ϭ 0.5 hr and a comparison of the mean dihydroartemisin C t1 ϭ 0.5 hr with the mean dihydroartemsinin C t2 ϭ 0.5 hr showed that the plasma levels 30 min after the second administration were not necessarily higher than 30 min after the first administration. It is possible that a second administration of artesunate 3 hr after the first administration might prove to be more effective.
The rapid parasite clearance and fever clearance after rectal artesunate administration showed its potential therapeutic value as an initial treatment in African children with uncomplicated P. falciparum malaria. In spite of the low dose administered and the small volume of blood sample collected, the quantification of plasma levels of artesunate and dihydroartemisinin was feasible. The data thus obtained made it possible to evaluate the plasma level versus time relationship and provided a basis for an analysis of the kinetic profiles of artesunate and dihydroartemisinin. It would now be of great interest to conduct further studies leading to greater details in pharmacokinetic data, also treating adults with severe malaria, as well as children.
